NSYNC entertainer diagnosed with rare form of diabetes that happens in adulthood but is more like Type 1 than Type 2.

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

The year-over-year revenue growth was driven by strong new patient performance and the expanded availability of its G7 and DexCom ONE+ product platforms. Following the earnings release ...

She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups. However ...

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...